329 related articles for article (PubMed ID: 25236925)
1. The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets.
Rocchi L; Caraffi S; Perris R; Mangieri D
Biosci Rep; 2014 Nov; 34(6):e00147. PubMed ID: 25236925
[TBL] [Abstract][Full Text] [Related]
2. Tumor angiogenesis and anti-angiogenic therapy.
Kubota Y
Keio J Med; 2012; 61(2):47-56. PubMed ID: 22760023
[TBL] [Abstract][Full Text] [Related]
3. Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself.
Yang QK; Chen T; Wang SQ; Zhang XJ; Yao ZX
Angiogenesis; 2020 Aug; 23(3):279-298. PubMed ID: 32333216
[TBL] [Abstract][Full Text] [Related]
4. Anti-angiogenic therapy, a new player in the field of sarcoma treatment.
Versleijen-Jonkers YM; Vlenterie M; van de Luijtgaarden AC; van der Graaf WT
Crit Rev Oncol Hematol; 2014 Aug; 91(2):172-85. PubMed ID: 24613529
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis inhibition in non-GIST soft tissue sarcomas.
Sleijfer S; van der Graaf WT; Blay JY
Oncologist; 2008 Nov; 13(11):1193-200. PubMed ID: 18987047
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic approach in soft-tissue sarcomas.
Martin-Liberal J; Judson I; Benson C
Expert Rev Anticancer Ther; 2013 Aug; 13(8):975-82. PubMed ID: 23944712
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenesis agents in the treatment of soft tissue sarcomas.
Ganjoo K; Jacobs C
Cancer; 2010 Mar; 116(5):1177-83. PubMed ID: 20052715
[TBL] [Abstract][Full Text] [Related]
8. Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma.
Yoon SS; Segal NH; Olshen AB; Brennan MF; Singer S
Ann Oncol; 2004 Aug; 15(8):1261-6. PubMed ID: 15277268
[TBL] [Abstract][Full Text] [Related]
9. Anti-angiogenic therapy in breast cancer.
Atiqur Rahman M; Toi M
Biomed Pharmacother; 2003 Dec; 57(10):463-70. PubMed ID: 14637390
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor 2 orchestrates angiogenic networking in non-GIST STS patients.
Kilvaer TK; Valkov A; Sorbye SW; Smeland E; Bremnes RM; Busund LT; Donnem T
J Transl Med; 2011 Jul; 9():104. PubMed ID: 21733164
[TBL] [Abstract][Full Text] [Related]
11. Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches.
Mocellin S; Rossi CR; Brandes A; Nitti D
Cancer Treat Rev; 2006 Feb; 32(1):9-27. PubMed ID: 16338075
[TBL] [Abstract][Full Text] [Related]
12. Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: a new treatment for metastatic soft tissue sarcoma.
Ranieri G; Mammì M; Donato Di Paola E; Russo E; Gallelli L; Citraro R; Gadaleta CD; Marech I; Ammendola M; De Sarro G
Crit Rev Oncol Hematol; 2014 Feb; 89(2):322-9. PubMed ID: 24041629
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of Soft Tissue Sarcoma Response to Gemcitabine through Timed Administration of a Short-Acting Anti-Angiogenic Agent.
Cheng J; Fuller J; Feldman R; Tap W; Owa T; Fuks Z; Kolesnick R
Cell Physiol Biochem; 2020 Jul; 54(4):707-718. PubMed ID: 32722909
[TBL] [Abstract][Full Text] [Related]
14. Targeting angiogenesis for the treatment of sarcoma.
Balasubramanian L; Evens AM
Curr Opin Oncol; 2006 Jul; 18(4):354-9. PubMed ID: 16721130
[TBL] [Abstract][Full Text] [Related]
15. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
Sleijfer S; Ray-Coquard I; Papai Z; Le Cesne A; Scurr M; Schöffski P; Collin F; Pandite L; Marreaud S; De Brauwer A; van Glabbeke M; Verweij J; Blay JY
J Clin Oncol; 2009 Jul; 27(19):3126-32. PubMed ID: 19451427
[TBL] [Abstract][Full Text] [Related]
16. Novel angiogenesis inhibitors: addressing the issue of redundancy in the angiogenic signaling pathway.
Ribatti D
Cancer Treat Rev; 2011 Aug; 37(5):344-52. PubMed ID: 21435792
[TBL] [Abstract][Full Text] [Related]
17. Dual-color imaging of angiogenesis and its inhibition in bone and soft tissue sarcoma.
Hayashi K; Yamauchi K; Yamamoto N; Tsuchiya H; Tomita K; Amoh Y; Hoffman RM; Bouvet M
J Surg Res; 2007 Jun; 140(2):165-70. PubMed ID: 17418866
[TBL] [Abstract][Full Text] [Related]
18. [Antiangionic drugs in soft tissue sarcoma].
Salas S; Huynh T; Deville JL; Duffaud F
Bull Cancer; 2010 Jun; 97(6):701-5. PubMed ID: 20483703
[TBL] [Abstract][Full Text] [Related]
19. Angiogenic profile of soft tissue sarcomas based on analysis of circulating factors and microarray gene expression.
Yoon SS; Segal NH; Park PJ; Detwiller KY; Fernando NT; Ryeom SW; Brennan MF; Singer S
J Surg Res; 2006 Oct; 135(2):282-90. PubMed ID: 16603191
[TBL] [Abstract][Full Text] [Related]
20. Placental growth factor upregulation is a host response to antiangiogenic therapy.
Bagley RG; Ren Y; Weber W; Yao M; Kurtzberg L; Pinckney J; Bangari D; Nguyen C; Brondyk W; Kaplan J; Teicher BA
Clin Cancer Res; 2011 Mar; 17(5):976-88. PubMed ID: 21343374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
